Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 05/16/23
Palatin Reports Third Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 05/16/23
Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023PRNewsWire • 05/11/23
Palatin Presents PL8177 Ulcerative Colitis Data at Digestive Disease Week Annual ConferencePRNewsWire • 05/09/23
Palatin Invites Investors to Listen to Replay of the PL9643 Dry Eye Disease Key Opinion Leader WebinarPRNewsWire • 05/08/23
Palatin Presents Initial Dry Eye Disease Phase 3 Clinical Data at the Association of Research in Vision and Ophthalmology 2023 Annual ConferencePRNewsWire • 04/27/23
Palatin Presents Data at the Association of Research in Vision and Ophthalmology 2023 Annual Conference Regarding a Potential Treatment for GlaucomaPRNewsWire • 04/25/23
Palatin Announces Preliminary Third Quarter Fiscal 2023 Vyleesi® Product Revenue ResultsPRNewsWire • 04/19/23
Pre-Clinical Data of Palatin's Melanocortin Agonist Demonstrating Therapeutic Effects in Diabetic Retinopathy and Uveitis Published in the International Journal of Molecular SciencesPRNewsWire • 04/18/23
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's Oral Formulation of PL8177 Demonstrating Therapeutic Effects in Inflammatory Bowel DiseasePRNewsWire • 03/02/23
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 02/15/23
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023PRNewsWire • 02/10/23
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney DiseasePRNewsWire • 01/19/23
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin's PL8177 Demonstrating Therapeutic Effects in Inflammatory ConditionsPRNewsWire • 01/10/23
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales ResultsPRNewsWire • 01/05/23
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 11/14/22
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate UpdatePRNewsWire • 11/14/22
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022PRNewsWire • 11/09/22
Palatin Presents PL8177 Data at American College of Gastroenterology Annual MeetingPRNewsWire • 10/24/22
First Patient Enrolled in Palatin's Phase 2 study of PL8177 in Ulcerative Colitis TrialPRNewsWire • 10/20/22
Palatin Announces Preliminary First Quarter Fiscal 2023 Vyleesi® Product Sales ResultsPRNewsWire • 10/13/22